Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Patient-centered Dosage of Levothyroxine

Patient-centered Decision Support Tool for Levothyroxine Dosage

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Levothyroxine is the most used thyroid hormone replacement when the thyroid gland is failing. Because dosage adjustment normally takes several months, the investigators have developed a decision support tool (DST) that predicts optimal dosage based on repeated blood samples the first 2 weeks after initiation of therapy. In this randomized study the investigators will include patients that start levothyroxine therapy after total thyroidectomy. The use of DST to advice the physician about an early dosage adjustment will be compared with common clinical practice, that is dosage adjustment every 2 months. The effect of DST use will be assessed by studying the possible relationship between fast optimal dose adjustment, patient reported outcome measures, and ability to work.

Who May Be Eligible (Plain English)

Who May Qualify: - Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals Who Should NOT Join This Trial: - Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Total or completion thyroidectomy for differentiated thyroid cancer og benign thyroid nodules at Norwegian hospitals Exclusion Criteria: * Anaplastic thyroid cancer, thyroid cancer with distant metastasis, graves disease, toxic nodules, pregnancy

Treatments Being Tested

OTHER

Decision support tool

Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.

Locations (3)

Haukeland University Hospital
Bergen, Norway
Oslo University Hospital
Oslo, Norway
University Hospital of North Norway
Tromsø, Norway